Friday, January 08, 2010
Biological Mechanisms Linking Obesity and Cancer Risk: New Perspectives - Annual Review of Medicine, 61(1):301 - Abstract
"While public health policies aimed at curbing the underlying causes of the obesity epidemic are being implemented, there is a parallel need to better understand the biological processes linking obesity and cancer as a prerequisite to the development of new approaches to prevention and treatment."
Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies* - Annual Review of Medicine, 61(1):35 - Abstract
Laboratory of Molecular Medicine and Neuroscience, Division of Intramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892; email: email@example.com
"Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the white matter of the human brain caused by lytic infection of oligodendrocytes with the human polyomavirus JCV. Although the majority of PML cases occur in severely immune-suppressed individuals, with HIV-1 infection as the predominant factor, PML has been increasingly diagnosed in patients treated with biological therapies such as monoclonal antibodies that modulate immune system functions...."
full free access
Some interesting observations in this article including:
"Per capita, Canada has one third fewer active physicians than the United States, 15% more primary care physicians, and half as many specialists. Consequently, the heavy responsibilities of Canadian specialists promote shared care with family physicians, and specialists rarely see patients without referral. In the United States, only 30% of visits to specialists occur through referrals,5 and patients are likely to see multiple specialists."
New Concepts in Organ Site Research:
Recent Advances in Ovarian Cancer Research
Co-Chairpersons: Christopher P. Crum, Brigham and Women's Hospital, Boston, MA, and Shelley S. Tworoger, Brigham and Women's Hospital, Boston, MA
* David D. Bowtell, Peter MacCallum Cancer Center, Melbourne, Australia
* Elise C. Kohn, National Cancer Institute, Bethesda, MD
* Martin Widschwendter, Institute for Women's Health, University College London, London, United Kingdom
* Alicja Wolk, National Institute of Environmental Medicine, Stockholm, Sweden
January 8th, 2009:
We are now accepting applications for the Advocates Partnership Program at the American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting, March 24-28 in Albuquerque, New Mexico.
The Advocates Partnership Program aims to foster new connections among members of the genetics community. Highlights for participants include engaging in thought-provoking discussions about clinical genetics and informatics, and attending exclusive daily briefings with ACMG staff and professionals working in your area of interest. The ACMG preliminary meeting schedule is available at http://www.acmgmeeting.net/schedule.php
Acceptance into the Advocates Partnership Program includes waived full registration to the ACMG Annual Clinical Genetics Meeting. Furthermore, participants will be reimbursed for up to $250 for transportation, hotel accommodations, or airfare.
We welcome applications from individuals interested in the field of clinical genetics. Individuals who hold ACMG membership or those who could be a potential candidate for membership are not eligible to apply for the Advocates Partnership Program.
To apply, please download the application form from http://www.geneticalliance.org/advocates.opportunities.
Please return it to firstname.lastname@example.org no later than Friday, February 5, 2010.
Priority will be given to individuals who previously have not participated in the Advocates Partnership Program.
Please forward this message to your friends and colleagues.
If you have any questions, please contact Tetyana Murza at email@example.com or (202) 966-5557 ext. 205. We look forward to hearing from you.
A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
Jan 7th, 2009 abstract and full free access